Table 2 SBRT parameters, outcomes, and adverse events (n = 16)
SBRT treatment, median (range) | |
|---|---|
SBRT dose, Gy | 45.0 (28–60) |
Number of fractions | 5 (4–5) |
EQD2, Gy | 71.25 (36.4–110.0) |
Tumor volume, cc | 35.9 (1.11–819.43) |
Number of targeted lesions | 2 (1–4) |
Normal liver volume, cc | 1281.7 (537.0–2095.1) |
rV15* of uninvolved liver, cc | 1019.6 (436.6–1610.2) |
SBRT outcomes, no. (%) | |
|---|---|
Radiographic response | |
Complete response (rCR) | 4 (25) |
Partial response (rPR) | 6 (37.5) |
Stable disease (rSD) | 6 (37.5) |
Local recurrence | |
Out-field | 11 (68.8) |
In-field | 0 |
AFP after SBRT**, median (range), IU/mL | 38.3 (2.8–386.3) |
Within Millan criteria after SBRT | 5 of 14 patients (35.7) |
Adverse events, no. (%) | Grade 1 | Grade 2 | Grade3 | Grade4 |
|---|---|---|---|---|
Biochemical | ||||
Albumin | 3 (18.8) | 3 (18.8) | 0 | 0 |
Alkaline phosphatase | 1 (6.3) | 0 | 0 | 0 |
ALT | 7 (43.8) | 0 | 0 | 0 |
AST | 7 (43.8) | 0 | 0 | 0 |
Bilirubin | 0 | 1 (6.3) | 1 (6.3) | 1 (6.3) |
Hematologic | ||||
Anemia | 3 (18.8) | 1 (6.3) | 1 (6.3) | 0 |
Leukocytopenia | 6 (37.5) | 1 (6.3) | 1 (6.3) | 0 |
Thrombocytopenia | 5 (31.3) | 1 (6.3) | 3 (18.8) | 0 |
Fatigue | 2 (12.5) | 0 | 0 | 0 |
Gastrointestinal toxicity | ||||
Abdominal pain | 2 (12.5) | 0 | 0 | 0 |
Anorexia | 1 (6.3) | 0 | 0 | 0 |
Diarrhea | 1 (6.3) | 1 (6.3) | 0 | 0 |
Nausea/vomiting | 1 (6.3) | 2 (12.5) | 0 | 0 |
RILD, no. (%) | |
|---|---|
Classic | 0 (0) |
Nonclassic | 1 (6.3) |